{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Esophageal&page=8", "query": { "condition": "Neoplasms, Esophageal", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1116, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Esophageal&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Esophageal&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T19:43:41.119Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03342937", "title": "KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "Oxaliplatin+Capecitabine+Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-01-11", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 7, "location_summary": "Clayton, North Carolina • Durham, North Carolina • Henderson, North Carolina + 4 more", "locations": [ { "city": "Clayton", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Henderson", "state": "North Carolina" }, { "city": "Laurinburg", "state": "North Carolina" }, { "city": "Lumberton", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03342937" }, { "nct_id": "NCT00526669", "title": "Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Gastrointestinal Tract" ], "interventions": [ { "name": "Lapatinib and Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2008-03", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-01-29", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 8, "location_summary": "Loma Linda, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526669" }, { "nct_id": "NCT00230451", "title": "Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Radiation", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": "1997-11", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2010-01-15", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00230451" }, { "nct_id": "NCT03505320", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pharmacokinetics of Zolbetuximab", "Gastric Cancer", "Gastro-esophageal Junction (GEJ) Cancer", "Pharmacokinetics of Oxaliplatin", "Pharmacokinetics of Fluorouracil Bolus (5-FU)" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-06-29", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 6, "location_summary": "Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03505320" }, { "nct_id": "NCT03228407", "title": "Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastro Esophageal Reflux", "Barrett Esophagus", "Erosive Esophagitis" ], "interventions": [ { "name": "Confocal endomicroscopy", "type": "PROCEDURE" }, { "name": "Endoscopic biopsies", "type": "DIAGNOSTIC_TEST" }, { "name": "Mucosal impedance (MI)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "McGuire Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2017-04-28", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228407" }, { "nct_id": "NCT03042611", "title": "A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "Rivoceranib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2017-03-14", "completion_date": "2020-09-23", "has_results": true, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hawthorne", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042611" }, { "nct_id": "NCT00020787", "title": "Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "G17DT Immunogen", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2001-07", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020787" }, { "nct_id": "NCT01285557", "title": "Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction" ], "interventions": [ { "name": "S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)", "type": "DRUG" }, { "name": "Fluorouracil/cisplatin (control arm)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2011-04-14", "completion_date": "2014-08-15", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 4, "location_summary": "Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more", "locations": [ { "city": "Alexandria", "state": "Louisiana" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285557" }, { "nct_id": "NCT02282111", "title": "EUS-CNB Versus EUS-SINK for Diagnosis of Upper Gastrointestinal (UGI) Subepithelial Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Subepithelial Lesions" ], "interventions": [ { "name": "22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)", "type": "DEVICE" }, { "name": "conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 56, "start_date": "2014-07", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282111" }, { "nct_id": "NCT06065371", "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Sacituzumab govetican", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-11-20", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-11T19:43:41.119Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065371" } ] }